An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid

Journal of Occupational and Environmental Medicine

Volumn 40, Issue 7, 1998, Pages 614-622

  Olsen, Geary W ^a   Gilliland, Frank D ^b   Burlew, Michele M ^a   Burris, Jean M ^a   Mandel, Jack S ^a   Mandel, Jeffrey H ^c  

^a 3M COMPANY   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; HYDROCORTISONE; LUTEINIZING HORMONE; PERFLUOROOCTANOIC ACID; PEROXISOME PROLIFERATOR; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ARTICLE; CHEMICAL CARCINOGENESIS; ESTRADIOL BLOOD LEVEL; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; REPRODUCTION; RISK FACTOR; TESTOSTERONE BLOOD LEVEL;

ADULT; ANALYSIS OF VARIANCE; CHEMICAL INDUSTRY; CROSS-SECTIONAL STUDIES; DATA COLLECTION; ENVIRONMENTAL MONITORING; EPIDEMIOLOGIC METHODS; ESTRADIOL; FLUOROCARBONS; HUMANS; MALE; MIDDLE AGED; MINNESOTA; OCCUPATIONAL EXPOSURE; OCTANOIC ACIDS; SAMPLING STUDIES; TESTOSTERONE;

ANIMALIA;

EID: 0031825683     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043764-199807000-00006     Document Type: Article

References (43)

1. Bryce H. Industrial and utilitarian aspects of fluorine chemistry. In: Simons J, ed. Fluorine Chemistry. New York: Academic Press; 1964:297-492.
2. Nickles M. Presence du fluor dans la sang. Compt Rend. 1856;43:885.
3. Taves D. Evidence that there are two forms of fluoride in human serum. Nature. 1968;217:1050-1051.
4. Taves D. Electrophoretic mobility of serum fluoride. Nature. 1968;220:582-583.
5. Guy W. Fluorocompounds of Human Plasma: Analysis, Prevalence, Purification, and Characterization. [Doctoral dissertation.] Rochester, NY: University of Rochester; 1972.
6. Griffith FD, Long JE. Animal toxicity studies with ammonium perfluorooctanoate. Am Ind Hyg Assoc J. 1980;41:576-583.
7. Kennedy G. Dermal toxicity of ammonium perfluorooctanoate. Toxicol Appl Pharmacol. 1985;81:348-355.
8. Kennedy G, Hall G, Brittelli J, Chen H.. Inhalation toxicity of ammonium perfluorooctanoate. Food Chem Toxicol. 1986; 24:1325-1329.
9. Ophaug R, Singer L. Metabolic handling of perfluorooctanoic acid in rats. Proc Soc Exp Biol Med. 1980;163:19-23.
10. Ylinen M, Koho A, Hanhijarvi H, Peura P. Disposition of perfluorooctanoic acid in the rat after single and subchronic administration. Bull Environ Contam Toxicol. 1990;44:46-53.
11. Vanden Heuvel J, Kuslikis B, Van Refelghem M, Peterson R. Tissue distribution, metabolism and elimination of perfluorooctanoic acid. J Biochem Toxicol. 1991;6:83-92.
12. Kuslikis BI. Vanden Heuvel JP, Peterson RE. Lack of evidence for perfluorodecanoyl- or perfluorooctanoyl-coenzyme A formation in male and female rats. J Biochem Toxicol. 1992;7:25-29.
13. Hanhijarvi H, Phaug R, Singer L. The sex-related difference in perfluorooctanoate excretion in the rat. Proc Soc Exp Biol Med. 1982;171:51-55.
14. Hanhijarvi H, Ylinen M, Kojo A, Kosma VM. Elimination and toxicity of perfluorooctanoic acid during subchronic administration in the Wistar rat. Pharmacol Toxicol. 1987;61:66-68.
15. Ikeda T, Aiba K, Fukuda K, Tanaka M. The induction of peroxisome proliferation in rat liver by perfluorinated fatty acids, metabolically inert derivatives of fatty acids. J Biochem. 1985;98:475-482.
16. Pastoor TP, Lee KP, Pern MA, Gillies PJ. Biochemical and morphological studies of ammonium perfluorooctanoate-induced hepatomegaly and peroxisome proliferation. Exp Mol Pathol. 1987;47: 98-109.
17. Sibinski LJ. Two-Year Oral (Diet) Toxicity/Carcinogenicity Study of Fluorochemical FC-143 in Rats. St. Paul, MN: Riker Laboratories; 1987.
18. Cook JC, Murray SM, Frame SR, Hurtt ME. Induction of Leydig cell adenomas by ammonium perfluorooctanoate: a possible endocrine-related mechanism. Toxicol Appl Pharmacol. 192;113:209-217.
19. Biegel LB, Liu RCM, Hurtt ME, Cook JC. Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo, and ex vivo studies. Toxicol Appl Pharmacol. 1995;134:18-25.
20. Liu RCM, Hurtt ME, Cook JC, Biegel LB. Effect of the peroxisome proliferator, ammonium perfluorooctanoate (C8), on hepatic aromatase activity in adult male CRl:CD BR (CD) rats. Fundam Appl Toxicol. 1996;30:220-228.
21. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Ann Rev Cell Dev Biol. 1996;12:335-363.
22. Cook JC, Hurtt ME, Frame SR, Biegel LB. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in Crl:CD BR (CD) rats. Toxicologist. 1994; 14:301 (abstract).
23. Ogbourn JD, Frame SR, Elliot GS, Cook JC. Pancreatic oncogenic effects of Wyeth 14,643. Toxicologist. 1997;36:232 (abstract).
24. Rao MS, Reddy JK. Hepatocarcinogenesis of peroxisome proliferators. Ann NY Acad Sci. 1996;804:573-587.
25. Palazzolo MJ. 13-Week Dietary Toxicity Study with T-5180, Ammonium Perfluorooctanoate (CAS No. 3825-26-1), in Male Rats. Madison, WI: Hazelton Laboratories; 1991.
26. Perkins RG. Investigation of ammonium perfluorooctanoate effect on hormone levels and peroxisomal proliferation in the rat. Toxicologist. 1992;12:38 (abstract).
27. Ubel FA, Sorenson SD, Roach DE. Health status of plant workers exposed to fluorochemicals, a preliminary report. Am Ind Hyg Assoc J. 1980;41:584-589.
28. Gilliland FD. Fluorocarbons and Human Health: Studies in an Occupational Cohort. [Doctoral dissertation.] Minneapolis, MN: University of Minnesota; 1992.
29. Pothapragada V. Sodium biphenyl method for determination of covalently bound fluorine in organic compounds and biological materials. Anal Chem. 1982; 54:1132-1137.
30. Gilliland FD, Mandel JS. Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med. 1993;35:950-954.
31. Simons J, Bryce T. Electrochemical fluorination. In: Simons J, ed. Fluorine Chemistry. New York: Academic Press; 1954:340-377.
32. Johnson JD, Wolter JT, Colaizy GE, Rethwill PA, Nelson RM. Quantification of perflurooctanoate and perfluorooctanesulfonate in human serum using ion-pair extraction and high performance liquid chromatography-thermospray mass spectrometry with automated sample preparation. [3M Environmental Laboratory Report.] St. Paul, MN: 3M Company; 1996.
33. SAS Institute, Inc. SAS Users Guide: Statistics. Version 6. Cary, NC: SAS Institute, Inc.; 1990.
34. Griffin JE, Wilson JD. Disorders of the testes. In: Isselbacker KJ, Braunwald E, Wilson JD, Martini JB, Fauci AS, Karper DL, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 1994:2006-2017.
35. Montgomery DC, Peck EA. Introduction to Linear Regression Analysis. New York: John Wiley and Sons, Inc.; 1992: 67-117.
36. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci. 1993;90:2160-2164.
37. Hunter J, Kassam A, Winrow CJ, Rachubinski RA, Capone JP. Crosstalk between the thyroid hormone and peroxisome proliferator-activated receptors in regulating peroxisome proliferator-responsive genes. Mol Cel Endocrinol. 1996;116: 213-221.
38. Stringer DA. Hepatic Peroxisome Proliferation. [Monograph No. 17.] Brussels: European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC); 1992.
39. De la Iglesia FA, McGuire ED, Haskins JR, Lalwani ND. Structural diversity of peroxisome proliferators and their effects on mammalian liver cells in vivo. Ann NY Acad Sci. 1996;804:310-327.
40. Tugwood JD, Aldridge TC, Lambe KG, MacDonald N, Woodyatt NJ. Peroxisome proliferator-activated receptors: structures and function. Ann NY Acad Sci. 1997;804:252-265.
41. Tugwood JD, Lambe KG, Woodyatt NJ. Inter-individual differences in human peroxisome proliferator-activated receptor alpha structure and function. Toxicologist. 1997;36:236 (abstract).
42. Olsen GW, Kusch GD, Stafford BA, Gudmundsen SL, Currier MF. The positive known association design: a quality assurance method for occupational health surveillance data. J Occup Med. 1991;33: 998-1000.
43. Goldzieher JW, Dozier TS, Smith KD, Steinberger E. Improving the diagnostic reliability of rapidly fluctuating plasma hormone levels by optimized multiple-sampling techniques. J Clin Endocrinol Metab. 1976;43:824-830.